Generic-Drug Industry Cites Reports in Call for Regulatory Reform

The European Generic medicines Association praised a preliminary report by the European Commission (EC) on inefficiencies in the pharmaceutical market and urged the EC to consider drug regulation changes to close loopholes that allow originator companies to delay introduction of “me too” drugs through lengthy patent disputes. The report, released late last year, found that EU healthcare providers could have saved an estimated $3.8 billion from 2000–2007 if the introduction of some generic medicines had not been delayed.
International Pharmaceutical Regulatory Monitor